Neuropharmacology publishes high quality, original research and review articles within the discipline of neuroscience, especially
articles with a neuropharmacological component. However, papers within any area of neuroscience will be considered. The journal does
not usually accept clinical research, although preclinical neuropharmacological studies in humans ... click here for full Aims & Scope
Neuropharmacology publishes high quality, original research and review articles within the discipline of neuroscience, especially
articles with a neuropharmacological component. However, papers within any area of neuroscience will be considered. The journal does
not usually accept clinical research, although preclinical neuropharmacological studies in humans may be considered. The journal only
considers submissions in which the chemical structures and compositions of experimental agents are readily available in the literature
or disclosed by the authors in the submitted manuscript. Only in exceptional circumstances will natural products be considered, and
then only if the preparation is well defined by scientific means. Neuropharmacology publishes articles of any length (original research
and reviews).
The scope of the journal is broad. It covers many disciplines and spans molecules (e.g., molecular biology, biochemistry)
through systems (e.g., neurophysiology) to behaviour (e.g. cognition, psychopharmacology). The journal covers all aspects of neuroscience
with an emphasis on neurotransmitters and their receptors, ion channels, signalling, psychcopharmacology and animal models of disease,
such as investigations on the neurobiology of cognition, depression, schizophrenia, anxiety, epilepsy, ischaemia, neuroprotection, neurodegeneration,
drugs of abuse and pain.
The journal publishes occasional Special Issues (and will consider publishing Supplements). Each year Elsevier/Neuropharmacology
organise a satellite symposium to the Meeting of the Society for Neuroscience . The journal publishes a Special Issue to accompany each
meeting. Please see http://www.neuropharmacology-conference.elsevier.com/ for details of this year's meeting and accompanying Special
Issue.
US National Institutes of Health (NIH) voluntary posting ("Public Access") policy
Neuropharmacology and Elsevier
facilitate the author's response to the NIH Public Access Policy. For more details please see the Guide for authors
Hide Aims & Scope
Editor -in Chief Contact the Editor
Graham Collingridge
20th Neuropharmacology Conference, in association with NC-IUPHAR, on
High Resolution Neuropharmacology - Structure changes the Paradigm will be held in San Diego, USA on 10th to 12th November 2010. More information:
www.neuropharmacology-conference.elsevier.com
Home | Elsevier Sites | Privacy Policy | Terms and Conditions | Feedback | Site Map | A Reed Elsevier Company